Growth Metrics

Apyx Medical (APYX) Liabilities and Shareholders Equity (2016 - 2026)

Apyx Medical filings provide 16 years of Liabilities and Shareholders Equity readings, the most recent being $66.8 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 3.08% to $66.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $242.6 million, a 7.31% decrease, with the full-year FY2025 number at $66.8 million, up 3.08% from a year prior.
  • Liabilities and Shareholders Equity hit $66.8 million in Q4 2025 for Apyx Medical, up from $57.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $79.2 million in Q4 2023 to a low of $51.8 million in Q4 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $62.7 million (2022), compared with a mean of $63.4 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: fell 24.66% in 2022 and later surged 53.05% in 2023.
  • Apyx Medical's Liabilities and Shareholders Equity stood at $68.7 million in 2021, then fell by 24.66% to $51.8 million in 2022, then surged by 53.05% to $79.2 million in 2023, then decreased by 18.17% to $64.8 million in 2024, then grew by 3.08% to $66.8 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $66.8 million (Q4 2025), $57.4 million (Q3 2025), and $58.2 million (Q2 2025) per Business Quant data.